secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECISION BIOSCIENCES INC (DTIL)
CIK:        0001357874
Form:       8-K
Filed at:   2024-11-04T23:59:59+00:00
Accession:  0000950170-24-120278
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precision BioSciences Q3 revenue $0.6M, net loss $16.4M; PBGENE-HBV enters clinic
--------------------------------------------------------------------------------

- Revenue $0.6M down from $13.1M YoY; net loss $16.4M ($2.25/share) vs $8.1M loss in Q3 2023.
- Cash $121.3M sufficient into H2 2026, supplemented by $22.5M loan from Banc of California (maturing June 2027).
- PBGENE-HBV CTA approved in Moldova; patient screening underway; Phase 1 data expected in 2025.
- PBGENE-3243 (mitochondrial disease) IND/CTA expected in 2025; regained rights to three Prevail programs under assessment.
- Appointed Dr. Murray Abramson SVP Head of Clinical Development and John Fry as Strategic Clinical Advisor for hepatitis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357874/000095017024120278/0000950170-24-120278-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357874/000095017024120278/dtil-20241104.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-120278

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer